

09/29/03

16805 U.S. PTO

**UTILITY
PATENT APPLICATION
TRANSMITTAL**(Only for new nonprovisional applications under 37
CFR 1.53(b))

Attorney's Docket No.: N0260.70066US00

First Named Inventor or Application Identifier

SHASHOUA, Victor

Express Mail Label No.

EV 292560636 US

Date of Deposit

September 29, 2003

09/29/03 U.S. PTO

09/29/03

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents

ADDRESS
TO:

Mail Stop Patent Application

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

1. ☐ Fee Transmittal Form
(Submit an original, and a duplicate for fee processing)2. ☒ Applicant claims small entity status.3. ☒ Specification [Total pages 52]

49 - pages description

1 - pages abstract

2 - pages claims

11 - Total claims

4. ☒ Drawing(s) (35 USC 113) [Total sheets 5]☒ Informal ☐ Formal [Total drawings 7]5. ☒ Oath or Declaration [Total pages 2]a. ☐ Newly executed (original or copy)b. ☒ Copy from a prior applicationi. ☐ **DELETION OF INVENTOR(S)**Signed statement attached deleting
inventor(s) named in the prior application,
see 37 CFR 1.63(d)(2) and 1.33(b).If 5b is checked the entire disclosure of prior
applications,Serial No. 09/021,247, filed February 10, 1998,
entitled "NEUROPROTECTIVE PEPTIDES AND
USES THEREOF," now U.S. Patent No. 6,225,444
B1.from which an oath or declaration is supplied, is
considered as part of the disclosure of the
accompanying application as is hereby incorporated by
reference therein. The incorporation can only be relied
upon when a portion has been inadvertently omitted
from the submitted application parts.6. ☒ Application Data Sheet, See 37 CFR 1.767. ☐ CD-ROM or CD-R, in duplicate, large
table or Computer Program (Appendix)
8. ☐ Nucleotide and/or Amino Acid Sequence
Submission (if applicable, all necessary)a. ☐ Computer Readable Form (CRF)b. ☐ Specification Sequence Listing on:i. ☐ CD-ROM or CD-R (2 copies); orii. ☐ paper (identical to computer copy)c. ☐ Statement verifying identity of above copies**ACCOMPANYING APPLICATION PARTS**9. ☐ Assignment Papers/cover sheet &
documents(s)10. ☐ 37 CFR 3.73(b) Statement
(when there is an assignee)
☐ Power of Attorney11. ☐ English Translation of Document (if applicable)12. ☐ Information Disclosure Statement PTO-1449
☐ Copies of IDS Citations13. ☐ Preliminary Amendment14. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)16. ☐ Request and Certification Under 35 U.S.C.
§122(b)(2)(B)(ii)17. ☐ Other:

18. NOTE TO PRACTITIONERS: If a CONTINUING APPLICATION, supply the requisite priority or continuity information in (1) the body of the application, or in a preliminary amendment, and (2) in an Application Data Sheet under 37 CFR 1.76.


This application is a continuation of and claims priority to application serial number 09/810,863, filed March 16, 2001, entitled "Neuroprotective Peptides and Uses Thereof," now allowed, which is a divisional of and claims priority to application serial number 09/021,247, filed February 10, 1998, entitled "Neuroprotective Peptides and Uses Thereof," now U.S. Patent No. 6,225,444, issued May 1, 2001, the entire disclosures of which are incorporated herein by reference.

19. CORRESPONDENCE ADDRESS

Correspondence address below

CUSTOMER NUMBER:
23628

OR (do NOT use both)

ATTORNEY'S NAME					
FIRM NAME					
ADDRESS					
CITY		STATE		ZIP	
COUNTRY		TELEPHONE		FAX	
20. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED					
NAME	Helen C. Lockhart, Ph.D., Reg. No. 39,248				
SIGNATURE					
DATE	September 29, 2003				